Context Therapeutics Inc

Company Profile

Context Therapeutics Inc had its IPO on 2021-10-20 under the ticker symbol CNTX.

The company operates in the Healthcare sector and Biotechnology industry. Context Therapeutics Inc has a staff strength of 9 employees.

Stock update

Shares of Context Therapeutics Inc opened at $1.11 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.05 - $1.11, and closed at $1.05.

This is a -2.78% slip from the previous day's closing price.

A total volume of 36,354 shares were traded at the close of the day’s session.

In the last one week, shares of Context Therapeutics Inc have increased by +5%.

Context Therapeutics Inc's Key Ratios

Context Therapeutics Inc has a market cap of $17.88 million, indicating a price to book ratio of 0.3187 and a price to sales ratio of 0.

In the last 12-months Context Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-14871935. The EBITDA ratio measures Context Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Context Therapeutics Inc’s operating margin was 0% while its return on assets stood at -28.65% with a return of equity of -47.77%.

In Q1, Context Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Context Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.63 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Context Therapeutics Inc’s profitability.

Context Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.5966. Its price to sales ratio in the trailing 12-months stood at 0.

Context Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$31.97 million

Total Liabilities

$3.23 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Context Therapeutics Inc ended 2024 with $31.97 million in total assets and $0 in total liabilities. Its intangible assets were valued at $31.97 million while shareholder equity stood at $28.73 million.

Context Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $3.23 million in other current liabilities, 15966.00 in common stock, $-50398697.00 in retained earnings and $0 in goodwill. Its cash balance stood at $29.77 million and cash and short-term investments were $29.77 million. The company’s total short-term debt was $31,669 while long-term debt stood at $0.

Context Therapeutics Inc’s total current assets stands at $31.89 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.21 million and inventory worth $0.

In 2024, Context Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Context Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.05

52-Week High

$2.52

52-Week Low

$0.47

Analyst Target Price

$

Context Therapeutics Inc stock is currently trading at $1.05 per share. It touched a 52-week high of $2.52 and a 52-week low of $2.52. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $1.15 and 200-day moving average was $0.91 The short ratio stood at 1.13 indicating a short percent outstanding of 0%.

Around 682.4% of the company’s stock are held by insiders while 2380.4% are held by institutions.